ACE2 and prostate cancer: Among the top 10 drug candidates for the SARS-CoV-2 virus with the lowest IC50i.e., Verteporfin has been already validated as the potential ACE2 inhibitor in the in vitro and mouse model [34], which has primarily been used to treat age-related degeneration [35], and various types of cancers like prostatic cancer, breast cancer, etc [36].